Compare UNFI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNFI | TARS |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | 25600 | N/A |
| Industry | Food Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 1996 | 2020 |
| Metric | UNFI | TARS |
|---|---|---|
| Price | $49.84 | $56.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $44.71 | ★ $89.00 |
| AVG Volume (30 Days) | 576.9K | ★ 1.2M |
| Earning Date | 06-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.78 | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $0.47 | $56.43 |
| Revenue Next Year | $2.18 | $30.19 |
| P/E Ratio | $62.33 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $24.88 | $38.51 |
| 52 Week High | $57.02 | $85.25 |
| Indicator | UNFI | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 41.00 |
| Support Level | $48.17 | N/A |
| Resistance Level | $53.37 | $67.14 |
| Average True Range (ATR) | 1.75 | 4.36 |
| MACD | 0.28 | -0.82 |
| Stochastic Oscillator | 82.54 | 13.33 |
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.